MEI Pharma Inc (NASDAQ: MEIP), a late-stage pharmaceutical company, has reported its financial results for the quarter ended 30 September 2020, on Tuesday.

The company reported revenues of USD3.8m for the quarter ended 30 September 2020, compared to USD1.2m for the quarter ended 30 September 2019.

The firm posted net loss of USD2.1m, or USD 0.02 per share, for the quarter ended 30 September 2020, compared to net loss of USD3m, or USD0.04 per share for the same period in 2019.

Daniel P Gold, PhD, president and chief executive officer of MEI Pharma, said, 'As we move through fiscal year 2021, we are well-positioned and well-capitalised to achieve our goals across our pipeline. Importantly, we remain focused on advancing zandelisib toward commercialisation with our partner Kyowa Kirin and establishing its potential as an important treatment option in multiple lines of treatment across various B-cell malignancies. Our immediate focus is the completion of enrollment in the TIDAL study evaluating patients with follicular lymphoma, a study intended to support our accelerated approval strategy with FDA. TIDAL enrollment is expected to be completed in the first quarter of 2021 subject, of course, to developments in the global COVID-19 pandemic.'